Tox In Focus

Focused Clinical Reference

Vol. 35 · Acetaminophen · July 2026

Drug Quick Reference

Drug Class / Mechanism

Antipyretic / analgesic (APAP)

OTC and in opioid combination products

Found In

Tylenol; 200+ combination products

Vicodin, Percocet, Norco (with opioids)

Routes of Administration

Oral (therapeutic)

Commonly Detected With

Hydrocodone, oxycodone combinations · Cough/cold products; dextromethorphan

Metabolism

>90% hepatic conjugation, renal

~2% unchanged; half-life 4 to 11 h

Window of Detection

Urine parent ~1 to 2 days

Chronic use generally exceeds cutoff

Control Status

OTC; not scheduled

ACETAMINOPHEN

Confirming exposure in opioid combination products, and the hepatotoxicity risk

Acetaminophen (APAP) is an OTC analgesic and antipyretic present in more than 200 products, including opioid combinations (hydrocodone/APAP, oxycodone/APAP). Monitoring can verify use of a combination product and flag exposure in patients at risk of hepatic toxicity.¹

Why This Matters Now

Because many prescribed opioids are formulated with acetaminophen, its presence or absence is meaningful: a patient prescribed hydrocodone/APAP who tests APAP-negative may not be taking the combination product as prescribed. Acetaminophen also carries dose-dependent hepatotoxicity, with irreversible liver damage possible above ~10 g and even at 4 g/day in susceptible patients (alcohol use, hepatitis, enzyme inducers).²

⚠ Interpret acetaminophen alongside the prescribed opioid combination product, and consider cumulative APAP intake from multiple sources; hepatotoxicity risk rises with alcohol use and enzyme-inducing drugs like phenobarbital.

Clinical Presentation

OVERDOSE / TOXICITY

Early: often asymptomatic or nausea

Hepatotoxicity (delayed, 24 to 72 h)

Elevated transaminases, RUQ pain

Hepatic failure (severe overdose)

N-acetylcysteine is the antidote

CLINICAL USES

Verify combination-product adherence

Assess exposure in at-risk patients

Confirm elimination before a new agent

No withdrawal syndrome

Interpret with cumulative intake

Important: Acetaminophen overdose is a leading cause of acute liver failure and can be clinically silent early; N-acetylcysteine is the antidote and is most effective when started early. Cumulative dose from combination products and OTC sources adds up.

UDT Considerations

Acetaminophen is measured by immunoassay and reported semi-quantitatively in mcg/mL; in chronic users, urinary parent drug generally exceeds the cutoff.³ The test confirms exposure but does not identify the source or dose. Its main value is confirming or excluding use of an opioid combination product and flagging exposure in patients at hepatic risk.

Clinical Guidance

Interpret acetaminophen presence or absence against the prescribed opioid combination product.¹
Consider cumulative APAP from combination products and OTC sources in hepatotoxicity risk.²
Recognize higher risk with alcohol use, hepatitis, and enzyme-inducing drugs (e.g., phenobarbital).
Use the test to confirm exposure, not to estimate dose or timing.
For suspected overdose, treat clinically (N-acetylcysteine); this monitoring assay is not an overdose triage tool.

Point-of-Care Testing Availability

Available strips

Acetaminophen is measured by immunoassay (EIA), semi-quantitatively.

Clinical use

Its presence or absence matters for opioid combination-product adherence.

Limitations

The test confirms exposure, not dose or source.

ACETAMINOPHEN | Clinical & Program Guidance

Tox In Focus Vol. 35 · July 2026 · Page 2 of 2

Interpreting the Test Result

▲ If Testing Is Positive

Confirms acetaminophen exposure. Detection indicates use within roughly 1 to 2 days; chronic users generally exceed the cutoff.

Supports combination-product use. A positive is consistent with a prescribed opioid/APAP product.

Source not specified. OTC and combination products are indistinguishable by this test.

▼ If Testing Is Negative or Not Done

May question combo-product adherence. APAP-negative in a patient on hydrocodone/APAP warrants review.

Short window. Detection is about 1 to 2 days; a negative may reflect timing.

Timing and cutoff. Absence may reflect timing of last use or levels below the cutoff.

Metabolism & Urinary Markers

Acetaminophen analytes.

Metabolite	Clinical Significance
Acetaminophen (parent)	The immunoassay target; ~2% excreted unchanged; half-life 4 to 11 h.
Conjugated metabolites	Glucuronide, sulfate, cysteine, mercapturate; over 90% of the dose.

Key References

American Liver Foundation. Acetaminophen and your liver.
Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 8th ed. Biomedical Publications; 2008.
Perrone J, et al. Predictive properties of a qualitative urine acetaminophen screen in patients with self-poisoning. Clin Toxicol. 1999;37(6):769-772.

DISCLAIMER: This document is intended for clinical reference and educational purposes only. It does not constitute medical, legal, or professional advice and should not replace independent clinical or programmatic judgment. Content reflects published data available at time of preparation. ToxiPharm LLC makes no warranties regarding completeness or applicability in all settings. | © 2026 ToxiPharm LLC | toxipharm.org